Search results
Showing 1546 to 1560 of 8221 results
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)
Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) (TA1105)
NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1105
Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.
Show all sections
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)
NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.
Show all sections
Sections for TA1102
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.